-
Awarded03/08/2026
-
Today06/09/2026
Utilities
- indicates text translated automatically in your browsing language
Announcement of awarded contracts according to §130 c SGB V for the preparation with the active substance galcanezumab (emgality)
§ 130a(8) SGB V / §130c(1) SGB V enables health insurance funds (KK) and pharmaceutical companies to conclude discount agreements on the medicinal products to be dispensed at the expense of the statutory health insurance funds. GWQ acts as a company for efficiency and quality at KK in accordance with Section 130a(8) sentence 5 SGBV for its shareholder and customer funds. With regard to the relevant legal regulations for the award of public contracts, a regular process of drug-related, formal procurement procedures according to the regulations of the 4th part of the GWB by GWQ ServicePlus AG takes place. Contract start date is 01.07.2026
Type: price
Description: -
Weight (percentage, exact):
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.